Experimental Multiple Myeloma Treatments
Experimental myeloma treatments are treatments that are still being evaluated by the US Food & Drug Administration (FDA). Various experimental agents are now showing promise in multiple myeloma treatment. New biological agents hold the promise of efficacy through novel mechanisms of action, with a significant reduction of dose-limiting toxicities compared with classic cytotoxic chemotherapeutics. Proteasome inhibitors and immunomodulatory agents are furthest along in clinical development, and histone deacetylase inhibitors, heat shock protein 90 inhibitors, Akt inhibitors and monoclonal antibodies are some of the other agents entering later-phase clinical trials. Specific experimental treatments that are currently being studied by the FDA include:
For more information on experimental myeloma treatments, visit the Multiple Myeloma Knowledge Center.